贝伐单抗联合化疗治疗肺癌的效果研究

Study on effect of bevacizumab combined with chemotherapy in the treatment of lung cancer

目的探讨贝伐单抗联合化疗治疗晚期非小细胞肺癌(NSCLC)患者的临床治疗效果。方法选取2015年5月-2018年12月东莞市人民医院收治的70例晚期NSCLC患者作为研究对象,采用随机数字表法分为观察组和对照组,每组各35例。对照组患者给予单纯化疗,观察组在对照组基础上加以贝伐单抗治疗。观察两组患者治疗后的临床疗效、疾病控制率(DCR)、毒副反应及远期生存情况。结果观察组患者DCR明显高于对照组,差异有统计学意义(P<0.05)。观察组治疗过程中的毒副反应与对照组比较,差异无统计学意义(P>0.05)。观察组无进展生存期(PFS)和总生存期(OS)较对照组明显延长,差异均有统计学意义(P<0.05)。结论贝伐单抗联合化疗在短期疾病控制及长远生存期方面均较单纯化疗更加具有优势,并且不会增加患者在治疗期间的毒副反应。

Objective To investigate the clinical efficacy of bevacizumab combined with chemotherapy in the treatment of patients with advanced non-small cell lung cancer(NSCLC). Methods Seventy patients with advanced NSCLC admitted to Dongguan People’s Hospital from May 2015 to December 2018 were selected as research objects and divided into observation group and control group by random number table method,35 patients in each group. The patients in the control group were treated with chemotherapy alone,while the patients in the observation group were treated with bevacizumab on the basis of the control group.The clinical efficacy,disease control rate(DCR),adverse reactions and long-term survival of the two groups were observed. Results The DCR of the observation group was significantly higher than that of the control group,and the difference was statistically significant(P<0.05). The side effects of the observation group were compared with those of the control group,the differences were no statistically significant(P >0.05). The progression-free survival(PES) and overall survival(OS) in the observation group were significantly prolonged than that of the control group,the differences were statistically significant(P<0.05). Conclusion The bevacizumab combined with chemotherapy had advantages over chemotherapy alone in terms of shortterm disease control and long-term survival,and did not increase the adverse reactions of patients during treatment.